Apr 17 |
Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch
|
Apr 9 |
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
|
Apr 4 |
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
|
Mar 19 |
Tempest Therapeutics GAAP EPS of -$1.91 beats by $0.03
|
Mar 19 |
Tempest Reports Year End 2023 Financial Results and Provides Business Update
|
Mar 12 |
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
|
Mar 5 |
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
|
Feb 26 |
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
|
Dec 1 |
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
Nov 20 |
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
|